Meta-analysis of efficacy and safety of perampanel in treatment of refractory partial-onset seizures
10.7501/j.issn.1674-6376.2017.08.026
- VernacularTitle:吡仑帕奈治疗难治性癫痫部分发作的Meta分析
- Author:
gang Ke WU
1
;
yang Xiao HE
Author Information
1. 南部县人民医院神经外科
- Keywords:
perampanel;
refractory seizures;
drug combination;
drug safety;
Meta-analysis
- From:Drug Evaluation Research
2017;40(8):1157-1162
- CountryChina
- Language:Chinese
-
Abstract:
Objective o evaluate the efficacy and safety of perampanel in the treatment of refractory partial-onset seizures.Methods The randomized controlled trials ofperampanel in treatment of refractory partial-onset seizures were searched from PubMed,EBSCO,EMbase,Cochrane Library,CBM,CNKI,VIP database,and Wanfang database by computer.Data were collected from establishment of the database to February 2017 and the each index was analyzed by meta-analysis with RevMan 5.0 software.Results Five RCT were included,including 1 500 patients with refractory partial-onset seizures.Meta-analysis results showed that there was a significant difference between perampanel and placebo in term of seizure-free rate [OR=3.75,95％CI(1.77,7.93),P =0.000 6] and percentage of patients achieving 50％ reduction in seizure frequency [OR=2.08,95％CI(1.69,2.56),P ＜ 0.001].Common adverse reactions of perampanel were dizziness,somnolence,headache,ataxia,nasopharyngifis,etc.The total rate of adverse reactions of the two Perampanel groups of 8 mg group and 12 mg group doses were higher than placebo group (P ＜ 0.05).Conclusion The clinical efficacy of perampanel in the treatment of refractory partial-onset seizures,and the adverse reactions is slight,patient is well tolerated.
